EMA Grants Orphan Drug Status to Spinogenix’s SPG601 for Fragile X
July 7, 2025
FXS is a Common Inherited Form of Autism Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of